The National Institute of Immunology (NII) is dedicated to conduct progressive research with the objective of recognizing a human being’s defense mechanisms for increasing modalities of immune system operation that can interfere with disease progressions. The institute’s exploration boost areas under immunology and associated discipline clusters in infection and immunity, molecular design, gene guideline and reproduction and development, where critical research in modern biology is carried out utilizing various overlying disciplines of biochemistry, molecular biology, cell biology and structural biology.
In India, the Pharmaceutical business of The National Institute of Immunology is focused on Vaccine composition capable of inducing memory antibody response from single point immunization, Hemoglobin receptor as novel vaccine for leishmaniasis, Recombinant vaccine against infection and epsilon toxin intoxication and Bone Marrow-Derived Cells Ameliorates the Pathological Consequences of The Liver In Case Of Alpha1-Antitrypsin Deficiency.
The National Institute of Immunology filed patent application numbered 1465/DEL/2012 that is titled as DEVELOPMENT OF MEMBRANE BOUND EXPRESSION AND HETEROLOGOUS BOOSTER BASED DNA VACCINE AGAINST E-TOXIN OF CLOSTRIDIUM PERFRINGENS. The patent has been filed in the field of BIOTECHNOLOGY. This Patent Application has been granted as Patent Number 343601.
This invention covers Biotechnology. It describes a membrane bound expression-based DNA vaccine for inducing protective antibodies against Epsilon toxin (Etx) of Clostridium perfringens, comprising rDNA and a heterologous booster of SEQ.ID.NO. 2.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act that the claims of the present invention falls under the purview of section 3 (d) of The Patents Act 1970, as the said claims are claiming for a process/method of preparing DNA vaccine comprising different steps like cloning, culturing, expression, isolation etc.
As a response, Applicant submitted that u/s 3(d) the claims relates to a method of preparing a novel and inventive membrane-based DNA vaccine and heterologous booster wherein the resultant vaccine is capable of eliciting strong antibody titers and invokes both humoral and cell mediated immune response.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
